Kanada - inglise - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

Kanada - inglise - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Kanada - inglise - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 25mg - ranitidine (ranitidine hydrochloride) 25mg - histamine h2-antagonists

Kanada - inglise - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 75mg - ranitidine (ranitidine hydrochloride) 75mg - histamine h2-antagonists

Kanada - inglise - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Kanada - inglise - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

genpharm, l.p. - ranitidine (unii: 884kt10yb7) (ranitidine - unii:884kt10yb7) - tablet, film coated - 150 mg - ranitidine tablets are indicated in: 1.short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets, usp is indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

carilion materials management - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets, usp are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out